SOLUTION Group Bhd is hopeful that the Government will consider including its CanSino’s Convidecia vaccine as part of the booster dose programme to enhance the immune system against COVID-19 variants beginning early October.
In fact, the company’s wholly owned subsidiary Solution Biologics Sdn Bhd which is the ASEAN manufacturing partner for CanSino Biologics Inc’s single-dose Convidecia vaccine has expressed belief that its vaccine is an effective booster shot against COVID-19 variants.
“We have the infrastructure through our Fill and Finish facility and the capacity ready to take on the rise in demand,” commented Solution Group’s deputy group managing director Datuk Dr Mohd Nazlee Kamal.
“We can provide the booster shots for Malaysia and at the same time, supply to the ASEAN region.”
Data from a recent Chinese clinical study has shown that taking a booster shot with a single-dose Convidecia after receiving a two-dose inactivated vaccine is proven to be safe and able to effectively produce an immune response to the COVID-19 virus.
The study by Jiangsu Center of Disease Control published by MedRxiv before a peer review revealed that the Convidecia booster shot demonstrated an increase of at least 78-fold in average neutralising antibody levels in comparison with a booster shot with a similar inactivated vaccine with 15.2-fold increase in antibody levels.
The base for the study came from a randomised, controlled, observer-blinded trial of 300 participants aged between 18 and 59 years old who received one dose of Sinovac Biotech Ltd’s CoronaVac in the past one to three months or two doses in the past three to six months.
The study then compared Sinovac’s CoronaVac with CanSino’s Convidecia as a booster shot for safety and immune response.
“With the new data, we see that a booster dose of CanSino’s single-dose COVID-19 vaccine can help increase antibody responses among the study participants who had previously received one or two doses of inactivated vaccine,” observed Dr Mohd Nazlee.
Meanwhile, Solution Group said the supply agreement that Solution Biologics signed with the Health Ministry (MOH) to supply 3.5 million doses of its Convidecia vaccine will be fulfilled by November 2021, of which 300,000 doses were handed to the MOH last month.
“Another 2.6 million doses will be delivered by end-October with the entire supply of 3.5 million doses to be completed by November,” added Mohd Nazlee.
At 10am, Solution Group was up 1 sen or 1.5% to 67.5 sen with 576,200 shares traded, thus valuing the company at RM298 mil. – Sept 21, 2021.
